Related Experiment Video
Updated: Apr 15, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.3K
Challenges to integrating pharmacogenetic testing into medication therapy management
Susanne B Haga1, Nancy M Allen LaPointe, Jivan Moaddeb
1Duke University School of Medicine, 304 Research Dr., Box 90141, Durham, NC 27708. susanne.haga@duke.edu.
Journal of Managed Care & Specialty Pharmacy
|March 25, 2015
Summary
Integrating pharmacogenetic (PGx) testing into medication therapy management (MTM) could personalize drug treatments. However, the practical feasibility and clinical effectiveness of this approach require further investigation.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacy
- Genetics
Background:
- Pharmacogenetic (PGx) testing analyzes genetic variants to predict drug response, aiming to reduce adverse reactions and improve treatment efficacy.
- Medication Therapy Management (MTM) is a patient-centered service to optimize drug therapy.
- Integrating PGx into MTM could enhance treatment personalization and patient adherence by addressing concerns about side effects and perceived necessity.
Purpose of the Study:
- To explore the potential benefits of integrating pharmacogenetic testing into medication therapy management.
- To identify and discuss the challenges associated with the clinical implementation of PGx testing within MTM services.
Main Methods:
- This commentary discusses the theoretical framework and practical considerations for integrating PGx testing into MTM.
- It reviews existing literature and expert opinion on the feasibility and effectiveness of enhanced MTM.
Main Results:
- The integration of PGx testing into MTM holds promise for refining treatments and improving patient outcomes.
- Key challenges to implementation include logistical, educational, and economic factors that need to be addressed.
Conclusions:
- While PGx testing offers a pathway to "enhanced" MTM, its practical feasibility and effectiveness in real-world clinical settings remain undetermined.
- Further research and strategic planning are necessary to overcome the identified challenges and successfully integrate PGx into MTM services.
More Related Videos
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
194
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
194
01:27Pharmacogenetics of Drug Metabolism: Overview
157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
129
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
129
01:29Pharmacogenomics: Identification of New Drug Targets
94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
01:27Principles of Pharmacogenetics: Types of Genetic Variants
119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
239
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
239